Related Experiment Video

Updated: Apr 27, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K

Pityriasis versicolor: an update on pharmacological treatment options

Aditya K Gupta1, Danika C A Lyons

  • 1University of Toronto, Department of Medicine , Toronto , Canada.

Expert Opinion on Pharmacotherapy
|July 4, 2014
PubMed
Abstract

Insights

Pityriasis versicolor (PV) treatments are effective, but recurrence is common. Recent reviews modified systemic antifungal dosing, yet direct comparisons of topical and systemic agents remain inconclusive due to varied clinical trial reporting.

Area of Science:

  • Dermatology
  • Mycology
  • Infectious Diseases

Background:

  • Pityriasis versicolor (PV) is a common superficial fungal infection caused by Malassezia yeast.
  • Both topical and systemic treatments demonstrate high efficacy in clearing PV.
  • High recurrence rates persist despite successful initial treatment, with no established systemic antifungal dosing guidelines.

Purpose of the Study:

  • To review current and emerging treatments for Pityriasis versicolor.
  • To systematically evaluate the efficacy and dosing of established PV therapies.
  • To introduce novel therapeutic approaches for PV management.

Main Methods:

  • Literature search using "pityriasis versicolor" OR "tinea versicolor" keywords.
  • Focus on systematic reviews of existing treatments over the past decade.
  • Analysis of efficacy and dosing regimens of current PV therapies.

Main Results:

  • Established topical and systemic agents are effective for PV.
  • Systemic agent dosage recommendations have been updated based on new evidence.
  • Few novel treatments have emerged in the last ten years.

Conclusions:

  • Current treatments for PV are effective, but recurrence is a significant issue.
  • Updated dosing for systemic antifungals is available.
  • Lack of standardized clinical trial reporting prevents definitive comparison of treatment efficacy and safety.
Keywords:
pityriasis versicolorsystemic antifungaltinea versicolortopical antifungaltreatment

More Related Videos

Studying Chronic Exposure of Mice to Ultraviolet B Radiation03:20

Studying Chronic Exposure of Mice to Ultraviolet B Radiation

Published on: August 19, 2025

2.0K
Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

17.8K

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
102
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
91
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
999
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
3.3K